PG · The Procter & Gamble Company

The thesis

Procter & Gamble's sales growth stalled at 0% organic last quarter, and the shares are more likely to lag than lead the S&P 500 until volume grows again. The fiscal first-quarter report on 22 October 2026 settles it: it shows whether organic growth is moving toward the 1% to 3% the company guides for fiscal 2027.

The shares have firmed since the last update. They closed at $150.59 on 8 October 2026, up from $145.28 on 30 September 2026, helped by an Evercore ISI upgrade on 6 October 2026 and two sessions (28 September 2026 and 7 October 2026) in which defensive sectors led a falling market (Benzinga sector reports). None of that changes the business picture. In the fourth quarter of fiscal 2026, organic sales were flat, volume and price each contributed nothing, and core earnings per share (EPS), which exclude restructuring and other one-off items, fell 3% to $1.43 (company release, 29 July 2026).

The narrative is maturing: the slowdown has been public since the 29 July 2026 report, and the 6 October 2026 Evercore upgrade is the first fresh turn in sell-side opinion since then. The October report, more than analyst sentiment, decides whether the story re-accelerates.

Bullish and bearish views on The Procter & Gamble Company

The bull case on The Procter & Gamble Company (PG), in brief: Sell-side opinion is turning up. The bear case: Growth came from price, not units.

Bull case

• Sell-side opinion is turning up. Evercore ISI upgraded the shares from In Line to Outperform with a $166 target on 6 October 2026, and RBC Capital kept Outperform while trimming its target to $166 from $167 the same day (Benzinga, MarketBeat). MarketBeat counts 14 Buy and 10 Hold ratings with an average target of $161.70.
• Cash returns are large and funded. Fiscal 2026 operating cash flow was $19.6 billion, against $10.2 billion of dividends and $5.0 billion of buybacks (company release, 29 July 2026). The company plans about $10 billion of dividends and about $5 billion of buybacks in fiscal 2027.
• Guidance implies the low point is behind. Management guides 1% to 3% organic growth for fiscal 2027 after a flat fourth quarter (company release, 29 July 2026). A first quarter at the upper end of that range would mark a recovery.
• Defensive buying appears in weak sessions. On 7 October 2026, nine of 11 sectors fell while health care and consumer staples led (Benzinga). The shares rose 1.6% to about $148.34 on above-average volume on the day of the Evercore upgrade (MarketBeat, 6 October 2026).

Bear case

• Growth came from price, not units. Fiscal 2026 organic sales rose 1%, and the fourth quarter was flat with no contribution from volume (company release, 29 July 2026). A consumer products company that cannot add units depends on price increases that private-label rivals can undercut.
• Earnings growth guided near zero. Fiscal 2026 core EPS rose 1% to $6.89, and the fiscal 2027 range of $6.89 to $7.11 starts at that same figure (company release, 29 July 2026). The low end of guidance is no growth at all.
• Cost pressure is quantified and large. Management expects an after-tax headwind of about $1 billion from raw materials, energy and transportation in fiscal 2027 (company release, 29 July 2026).
• Hold ratings remain common. TD Cowen reiterated Hold with a $150 target on 30 September 2026, and Barclays rates the shares Equal Weight with a $152 target (MarketBeat). The 8 October 2026 close of $150.59 already sits at those targets.

Price setup

The 8 October 2026 close of $150.59 is 8.6% below the 52-week high of $164.72, and the shares are up 2.3% over three months (adjusted daily closes). MarketBeat put the 50-day moving average at $145.67 and the 200-day moving average at $145.97 on 6 October 2026, so the shares now trade above both averages, which sit almost on top of each other. The 14-day relative strength index (RSI), a momentum gauge on a 0 to 100 scale, reads 59.9, short of the 70 level usually read as overbought.

Crowding evidence is light. The price gap above the averages is narrow. MarketBeat reports insider sales of 15,135 shares worth about $2.19 million over the last 90 days, small for a company of this size, and there is no share issuance. The one crowding factor is timing: the 22 October 2026 report is less than three weeks away, and the recent gain came before any new business data.

Catalysts, next 30 days

• 13 October 2026, annual shareholder meeting. Held virtually at 9:00 a.m. Eastern Time (proxy statement, DEF 14A). A routine event that rarely moves the shares.
• ~13 October 2026, est., quarterly dividend declaration. The current quarterly dividend is $1.0885 per share (MarketBeat). A declaration at that amount confirms the roughly $10 billion fiscal 2027 dividend plan.
• 22 October 2026, fiscal first-quarter 2027 results. The company announced the webcast on 24 September 2026 (Business Wire). The report shows whether organic growth is above 0%, whether volume contributes, and whether the $6.89 to $7.11 core EPS range holds.

What would change the view

The case for lagging the index breaks if the 22 October 2026 report shows organic growth at or above the 3% top of the fiscal 2027 range with a positive volume contribution, alongside a reaffirmed or raised core EPS range. That would show the slowdown was a single soft quarter, and the Evercore upgrade would look early rather than late.

The view would also weaken if the shares hold above the 52-week high of $164.72 after the report, which would put the stock above the $161.70 average analyst target.

The deterioration case strengthens on a daily close below $144, under both the 50-day and 200-day moving averages and the 30 September 2026 close of $145.28. A cut to the $6.89 to $7.11 core EPS range on 22 October 2026, or a larger cost headwind than the roughly $1 billion guided, would show the slowdown deepening.

What it trades with

The shares trade with the consumer staples sector and with other defensive groups such as health care, rising in sessions when most sectors fall, as on 28 September 2026 and 7 October 2026 (Benzinga). That makes the stock a likely laggard in a broad rally led by growth stocks and a likely relative gainer in a sell-off. Results from household-products peers in October will shape expectations for P&G's volume trend, because private-label competition and input costs affect the whole group.